Skip to main content

Table 2 Evaluation at baseline, 6 and 12 months of 38 patients with idiopathic inflammatory myopathies after rituximab therapy

From: Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies

  Baseline 6 months 12 months Δ% (12 months vs. Baseline)
Prednisone dose (mg/day) 18.8 (10.0–36.3) 8.8 (2.5–15.0) 6.3 (0.0–16.3)
MMT-8 (0–80) 68.5 (56.8–72.5) 72.0 (67.0–78.0) 74.0 (70.0–78.0) + 11.3
HAQ (0.00–3.00) 1.00 (0.50–1.51) 0.63 (0.25–1.00) 0.50 (0.03–1.16) −53.0
Patient’s VAS (0–10 cm) 5.0 (3.0–7.0) 3.0 (1.0–5.0) 2.0 (0.0–4.0) − 57.0
Physician’s VAS (0–10 cm) 5.0 (3.8–7.0) 3.0 (1.0–4.3) 2.0 (1.0–4.0) −60.0
Creatine phosphokinase (U/L) 429 (123–971) 224 (83–527) 254 (83–551) −8.6
Aldolase (U/L) 5.5 (4.0–10.6) 3.9 (3.2–6.9) 3.6 (3.2–7.0) −29.0
Severe infections 0 0
Adverse events 0 2 (5.3)
Neoplasia 0 1 (2.6)
  1. Results expressed as percentage (%), or median (25th - 75th). VAS Visual Analogue Scale, MMT Manual Muscle Testing, HAQ Healthy Assessment Questionnaire, Δ% percentage variation